The Lead Episode 131: A Discussion of Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation: The DECAF Randomized Clinical Trial (English Language Episode)-A Discussion of Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation: The DECAF Randomized Clinical Trial (English Episode) Bonus Video

A Discussion of Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation: The DECAF Randomized Clinical Trial (English Episode) Bonus Video

Back to course

Video Transcription

Video Summary

This podcast episode discusses the Decaf Randomized Clinical Trial published in JAMA, studying the effects of caffeinated coffee consumption versus abstinence on atrial fibrillation (AF) recurrence. The trial involved 200 adults with persistent AF undergoing successful electrocardioversion, randomized into coffee consumption (≥1 cup/day) or abstinence groups, tracked over six months. Results showed that coffee consumption was associated with a significantly lower risk (39% reduction) and delayed time to AF recurrence compared to abstinence. Experts noted the impressive effect from just one cup daily, though they caution extrapolation to paroxysmal AF or higher coffee intake. Potential mechanisms include caffeine’s impact on sympathetic tone, anti-inflammatory effects, or vagal modulation. They emphasize individualized care, advising moderate coffee intake is likely safe post-AF treatment, complementing other lifestyle modifications. The study highlights the challenges of lifestyle trials and opens avenues for further research on caffeine’s role in AF management.

Keywords

Decaf Randomized Clinical Trial

atrial fibrillation recurrence

caffeinated coffee consumption

electrocardioversion

caffeine effects on AF